Today: 18 June 2026
Browse Category

NASDAQ:HCWB 15 May 2026 - 20 May 2026

HCW Biologics Jumps, Doubles Again as Traders Pile Into Biotech Name

HCW Biologics Jumps, Doubles Again as Traders Pile Into Biotech Name

HCW Biologics shares surged 122% to $2.35 Wednesday, trading as high as $3.96 on heavy volume after a new securities filing and recent earnings. The company is seeking up to $5.6 million in a stock or warrant offering to fund development of its IL-2 fusion protein, HCW9302. First-quarter revenue rose to $6.54 million, mainly from a licensing deal with Beijing Trimmune Biotech.
20 May 2026
·
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
16 May 2026
·
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
15 May 2026
·

Stock Market Today

  • IBM Stock Drops Amid Anticipation of Upcoming Earnings Report
    June 18, 2026, 10:08 AM EDT. IBM shares declined 4.32% in premarket trading Thursday ahead of its second-quarter earnings report scheduled for July 22. Analysts project IBM will report earnings per share (EPS) of $3 and revenue of $17.85 billion. This follows IBM's strong first-quarter performance with EPS of $1.91 and revenue of $15.92 billion, both exceeding estimates. Meanwhile, consulting rival Accenture revised its fiscal 2026 sales guidance lower and delivered mixed quarterly results, which may contribute to caution in the tech sector. Investors remain focused on IBM's upcoming report to assess whether the company can continue its streak of beating EPS expectations for the ninth consecutive quarter.

Latest articles

Kroger edges down after it sticks to 2026 guidance

Kroger edges down after it sticks to 2026 guidance

18 June 2026
Kroger shares fell about 3% in premarket trading after first-quarter adjusted profit missed estimates by a cent despite a sales beat, as margin pressure from price cuts and higher transport costs raised investor doubts about CEO Greg Foran’s strategy to win back shoppers from Walmart and Costco.
HIVE Digital shares jump in premarket after $220 million Bell-Cohere AI contract

HIVE Digital shares jump in premarket after $220 million Bell-Cohere AI contract

18 June 2026
HIVE Digital Technologies surged 11% in premarket trading after its BUZZ HPC unit landed a $220 million, three-year GPU cloud contract with Bell AI Fabric and Cohere, expected to add $70 million in annual recurring revenue and boost contracted AI-compute revenue above $100 million, as investors look for growth beyond bitcoin mining.
AT&T falls in early trading on CFO transition, spotlight on fiber costs

AT&T falls in early trading on CFO transition, spotlight on fiber costs

18 June 2026
AT&T shares slipped to $22.37 premarket as investors weighed CFO Pascal Desroches’ year-end retirement and Jennifer Biry’s 2027 succession amid heavy fiber and 5G spending, ongoing wireless competition from Verizon, and looming risks from SpaceX’s Starlink; next financial update set for July 22.
Go toTop